Daewoong Pharmaceutical presented successful clinical test data and various treatment procedures of its independently developed botulinum toxin “Nabota” at International Congress of Aesthetic Dermatology (ICAD) 2018 held in Bangkok, Thailand from Nov. 23-24.
The congress, which celebrates its 12th anniversary this year, is one of the most prestigious international aesthetic cosmetic conferences held annually in Thailand, and in this year’s conference, 1,200 aesthetic and plastic medicine officials from 60 countries attended.
In the symposium led by chairman Dr. Mart Maiprasert, a Thai dermatologist, Dr. Cristina Puyat, a dermatologist from Philippines, and Dr. Choi, Yoon-jin, head of Yonsei BB Skin Clinic, Korea, spoke to more than 2,000 subjects and showed major clinical outcomes in the United States, Europe and Canada. In addition, a variety of the latest treatments using Nabota received great attention from the participants.
"Nabota is a high purity product with more than 98% of the 900 Kda protein known to be the most stable and effective of botulinum toxin type A," said Dr. Cristina Puyat. "With the advantages of immediate onset of action and long duration, Nabota’s efficacy and safety have already been proven in clinics in Korea and developed countries."
In the meantime, Daewoong Pharmaceutical held the NABOTA Aesthetic Forum in Bangkok on the 24th, a separate event from the conference, which is a linkage education program for doctors of Asian countries. About 20 Korean and Thai doctors including Dr. Koh Kyung-suk from Samsung Lohas Clinic and Dr. Awika Rongthong of the Awikar Clinic attended the forum to share Nobota-using procedure cases and their opinions.